What is the amount of capital that has flowed into the space over the last two years 
is we added to the order book. We're not providing guidance yet.
But at the time and point when we're able to with confidence provide more color around things like order book and installs, we absolutely will. It's just still early for us. In terms of the emerging growth segment specifically, we directly haven't heard or seen too many people that at this point are rethinking purchasing decisions or rethinking their investment into their own businesses to advance their science. And I think that it's going to take some time.
I mean taking a step back, the figure that we quoted on the earnings call just a few moments ago, the number or the amount of capital that's flowing into the space over the last two years, a lot of that's going to need to be put to work. And people are going to need to spend that capital to advance their efforts internally. That being said, I think we're going to have to be adaptable to how customers want to step into a new technology or spend money. And that might be different solutions.
It might be reagent rental. It might be a capital lease. It might be just having to walk people through and show them how there's real cost savings holistically with one of our sequencers and their specific use case over the alternative. But the need is still there and these companies are well capitalized.
They're going to have to invest in it and a lot of that investment is going to need to be in sequencing to advance their own efforts.
Matt Sykes -- Goldman Sachs -- Analyst
Great. Thank you.
Operator
OK. The next question is coming from Michael Ryskin with Bank of America. Your line is live.
Mike Ryskin -- Bank of America Merrill Lynch -- Analyst
Great, excellent. Thanks for taking my questions, guys. Following up on the previous question, I want to start with the evaluation process for some of these customers. There's been some preliminary data published.
You've got your own data sets out there comparing the G4 with some comparator systems. But I want to go through the process that your customers and your potential customers are going through when they're making that purchasing decisions. Can you just walk us through the process? What data points are they looking at? Sort of how long is that validation process go? And sort of just if you could give us some case studies of that. Thanks.
Drew Spaventa -- Founder and Chief Executive Officer
Yes. So it really does vary by customer type. If you're talking about kind of academic labs, it's going to be a longer sales cycle in general. And there's probably going to be more back and forth over a longer period of time to really make sure that you have buy-in.
Academic cores typically have budgeting cycles, and you really want to start conversations early and get ahead and know who has budget for a new system and really have a more tailored approach to engaging and bringing them forward. And for the academic cores, cost is really a big part of it. So you have to understand the nuances of their applications. You have to walk them through how they would use the applications on your system.
You're going to have to provide data, whether it's publicly available or other data that's not publicly available yet, that we would engage with the customer and really get them confident that the system can perform. And once they're confident the system can perform, they're going to have to see a cost savings relative to alternatives typically. Now there's some academic cores that have specific value propositions, where the speed and the flexibility specifically makes it a very different dynamic for them to purchase. And again, those are where we want to, for a large part, focus our efforts, places where our competitive advantage really highlights the need to adopt our system versus others.
As we're thinking about other customers, whether they're emerging growth customers or commercial labs, typically with a private entity, it's a quicker buying decision, but there's still that hurdle where you need to get them comfortable the sequencer is going to meet their needs. So we offered and will con
is we added to the order book. We're not providing guidance yet.
But at the time and point when we're able to with confidence provide more color around things like order book and installs, we absolutely will. It's just still early for us. In terms of the emerging growth segment specifically, we directly haven't heard or seen too many people that at this point are rethinking purchasing decisions or rethinking their investment into their own businesses to advance their science. And I think that it's going to take some time.
I mean taking a step back, the figure that we quoted on the earnings call just a few moments ago, the number or the amount of capital that's flowing into the space over the last two years, a lot of that's going to need to be put to work. And people are going to need to spend that capital to advance their efforts internally. That being said, I think we're going to have to be adaptable to how customers want to step into a new technology or spend money. And that might be different solutions.
It might be reagent rental. It might be a capital lease. It might be just having to walk people through and show them how there's real cost savings holistically with one of our sequencers and their specific use case over the alternative. But the need is still there and these companies are well capitalized.
They're going to have to invest in it and a lot of that investment is going to need to be in sequencing to advance their own efforts.
Matt Sykes -- Goldman Sachs -- Analyst
Great. Thank you.
Operator
OK. The next question is coming from Michael Ryskin with Bank of America. Your line is live.
Mike Ryskin -- Bank of America Merrill Lynch -- Analyst
Great, excellent. Thanks for taking my questions, guys. Following up on the previous question, I want to start with the evaluation process for some of these customers. There's been some preliminary data published.
You've got your own data sets out there comparing the G4 with some comparator systems. But I want to go through the process that your customers and your potential customers are going through when they're making that purchasing decisions. Can you just walk us through the process? What data points are they looking at? Sort of how long is that validation process go? And sort of just if you could give us some case studies of that. Thanks.
Drew Spaventa -- Founder and Chief Executive Officer
 Yes. So it really does vary by customer type. If you're talking about kind of academic labs, it's going to be a longer sales cycle in general. And there's probably going to be more back and forth over a longer period of time to really make sure that you have buy-in.
Academic cores typically have budgeting cycles, and you really want to start conversations early and get ahead and know who has budget for a new system and really have a more tailored approach to engaging and bringing them forward. And for the academic cores, cost is really a big part of it. So you have to understand the nuances of their applications. You have to walk them through how they would use the applications on your system.
You're going to have to provide data, whether it's publicly available or other data that's not publicly available yet, that we would engage with the customer and really get them confident that the system can perform. And once they're confident the system can perform, they're going to have to see a cost savings relative to alternatives typically. Now there's some academic cores that have specific value propositions, where the speed and the flexibility specifically makes it a very different dynamic for them to purchase. And again, those are where we want to, for a large part, focus our efforts, places where our competitive advantage really highlights the need to adopt our system versus others.
As we're thinking about other customers, whether they're emerging growth customers or commercial labs, typically with a private entity, it's a quicker buying decision, but there's still that hurdle where you need to get them comfortable the sequencer is going to meet their needs. So we offered and will con